Home › NDC Lookup › Ingredients › Benzonatate › 23155-0898-01
Benzonatate 100 mg Capsule, Liquid Filled, 100-count — NDC 23155-0898-01 package photo

Benzonatate 100 mg Capsule, Liquid Filled, 100-count

by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. · 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (23155-898-01)
NDC 23155-0898-01
🏷️ FDA NDC (as labeled) 23155-898-01 billing pads the product segment with a zero
This package
Contains100-count Cost per ea$0.0656 NADAC Per package$6.56 / 100 capsules Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.3480/unit — full pricing hub ↓
Also comes in: 500 capsules 23155-0898-05
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

⚠️
Other active recalls for Benzonatate (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class III · Dec 26, 2023 — Superpotent drug: Assay results were slightly above specification at the time zero point. (Amerisource Health Services LLC) · FDA recall D-0257-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗

🆔 Identity & classification

FDA NDC (as labeled) 23155-898-01
Product NDC 23155-898
11-digit billing NDC 23155089801
NCPDP billing unit EA — each (per item)
RxCUI 197397, 283417
UNII 5P4DHS6ENR
Application # ANDA040682
SPL Set ID f32014c7-bc0c-4edb-b591-7baa6664d74b
Established class (EPC) Non-narcotic Antitussive
Physiologic effect Decreased Tracheobronchial Stretch Receptor Activity
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2024-09-29
Route ORAL
Dosage form CAPSULE, LIQUID FILLED
Substance BENZONATATE
GPI-14 43102010000105
GCN Seq No 004641
GCN 29840
HICL code 001929
Ingredient (HICL) Benzonatate
HIC1 code H
Therapeutic class — broad (HIC1) Nervous System (Except Autonomic)
HIC2 code H6
Therapeutic class — intermediate (HIC2) Drugs Acting Principally On The Midbrain
HIC3 code H6C
Therapeutic class — specific (HIC3) Antitussives, Non-Opioid
AHFS code 48:08.00.00
AHFS class Antitussives
FDB label name BENZONATATE 100 MG CAPSULE
FDB brand name Benzonatate
Legend status F — Federal legend — prescription drug or device
TE code (Orange Book) AA · RLD · RS
Why two NDCs? The FDA registers this code as 23155-898-01 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 23155-0898-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏷️ RxNorm drug class

This medicine belongs to the Non-narcotic Antitussive class.

Pharmacologic class Non-narcotic Antitussive
Drug family (ATC) Other cough suppressants
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

🏭 Manufacturer & labeler

LabelerHeritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
Application holderHERITAGE PHARMACEUTICALS LABS INC DBA AVET PHARMACEUTICALS LABS INC
FDA applicationANDA040682 (ANDA)
Labeler code23155
First marketedSep 2024
Product typeHuman Prescription Drug
Portfolio253 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name BENZONATATE 100 MG CAPSULE Ingredient Benzonatate
📗 Our plain-language guide HelloPharmacist
  • No, benzonatate is not related to codeine or narcotic cough medicines. Instead of working on your brain, it acts more like a local anesthetic inside your airways — it numbs the ner...
  • What exactly does benzonatate do — is it like cough syrup with codeine?
  • This is one of the most important things to know about benzonatate. The medicine inside acts like a numbing agent — if the capsule breaks open in your mouth, it can rapidly numb yo...
  • Why does my pharmacist keep telling me not to chew the capsule?
📖 Read our full Benzonatate guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

💊 What it looks like

Color yellow
ShapeOval
Imprint200
Size14 mm
ScoringNot scored
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 5138Q19F1X
    Ammonia is a colorless gas made from nitrogen and hydrogen. It's used in medicines as a pH buffer to maintain the correct acidity level and help keep the product stable.
  • UNII 8PJ61P6TS3
    Butyl alcohol is a clear liquid organic solvent derived from petroleum or natural sources. In medicines, it helps dissolve active ingredients and serves as a solvent in liquid formulations and some topical products.
  • UNII CQ3XH3DET6
    D&C Yellow No. 10 Aluminum Lake is a yellow colorant made by combining a dye with aluminum salts. It's used in medicines to add color for product identification and visual appeal.
  • UNII 92RU3N3Y1O
    Dimethicone is a silicone-based oil that acts as an anti-foaming agent and lubricant in medicines. It reduces gas bubbles in liquid formulations and helps coat and protect the stomach lining when ingested.
  • UNII 2G86QN327L
    Gelatin is a protein derived from animal collagen, commonly used in medicines as a gelling agent and capsule material. It helps create soft or hard capsule shells that hold and release medication, and can also thicken liquid formulations.
  • UNII PDC6A3C0OX
    Glycerin is a clear, thick liquid derived from plant oils or fats. It acts as a humectant to retain moisture, a sweetener, and a solvent in medications.
  • UNII ND2M416302
    Isopropyl alcohol is a clear liquid solvent derived from petroleum. In medicines, it dissolves active ingredients and other components, helps the product flow smoothly, and aids in sterilization during manufacturing.
  • UNII CR6K9C2NHK
    A synthetic preservative derived from methylparaben. It prevents bacterial and fungal growth in medicines, extending shelf life and maintaining product safety during storage.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII 625NNB0G9N
    A preservative derived from benzoic acid that prevents bacterial and fungal growth in medicines. It helps keep the product safe and stable throughout its shelf life.
  • UNII 46N107B71O
    Shellac is a natural resin secreted by the lac beetle. It's used as a coating on tablets and capsules to control how quickly the medicine dissolves and to improve appearance and stability.
  • UNII 15FIX9V2JP
    Titanium dioxide is a bright white mineral powder commonly used as a colorant and opacifying agent. It makes pills and tablets white or lighter in color and helps make coatings non-transparent.

12 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.066 $6.56 / 100 capsules
Medicaid paysCMS SDUD · 12 mo $0.3480 $34.80 / 100 capsules
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Dec 2025 Mar 2026 Jun 2026 Sep 2026 $0.073 $0.066
▼ Down 10% over the last 10 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Benzonatate 100 mg 00904-6564-60 Major 100 capsules $0.066 AA Availability likely —
Benzonatate 100 mg 00904-7153-61 Major 100 capsules $0.066 AA Availability likely —
Benzonatate 100 mgthis 23155-0898-01 Heritage 100 capsules $0.066 AA Availability likely —
Benzonatate 100 mg 31722-0956-01 Camber 100 capsules $0.066 AA Availability likely —
Benzonatate 100 mg 42806-0714-01 Epic 100 capsules $0.066 AA Availability likely —
Benzonatate 100 mg 62135-0440-31 Chartwell 300 capsules $0.066 AA Availability likely —
Benzonatate 100 mg 64380-0712-06 Strides 100 capsules $0.066 AA Availability likely —
Benzonatate 100 mg 64980-0634-01 Rising 100 capsules $0.066 AA Availability likely —
Benzonatate 100 mg 67877-0573-01 Ascend 100 capsules $0.066 AA Availability likely —
Benzonatate 100 mg 68084-0214-01 American 100 capsules $0.066 AA Availability likely —
Benzonatate 100 mg 68382-0247-01 Zydus 100 capsules $0.066 AA Availability likely —
Benzonatate 100 mg 69452-0143-20 Bionpharma 100 capsules $0.066 AA Availability likely —
Benzonatate 100 mg 51224-0010-50 TAGI 100 capsules $0.083 AA FDA listed +27%
Benzonatate 100 mg 00615-8403-39 NCS 30 capsules — AA FDA listed —
Benzonatate 100 mg 25000-0002-03 MARKSANS 30 capsules — AA FDA listed —
Benzonatate 100 mg 42291-0091-01 AvKARE 100 capsules — AA FDA listed —
Benzonatate 100 mg 49483-0946-01 TIME 100 capsules — AA FDA listed —
Benzonatate 100 mg 50090-4968-00 A-S 15 capsules — AA FDA listed —
Benzonatate 100 mg 50090-4969-00 A-S 20 capsules — AA FDA listed —
Benzonatate 100 mg 50090-5409-00 A-S 20 capsules — AA FDA listed —
Benzonatate 100 mg 50090-5986-00 A-S 15 capsules — AA FDA listed —
Benzonatate 100 mg 50090-6387-00 A-S 20 capsules — AA FDA listed —
Benzonatate 100 mg 50090-6850-00 A-S 15 capsules — AA FDA listed —
Benzonatate 100 mg 51655-0754-20 Northwind 20 capsules — AA FDA listed —
Benzonatate 100 mg 55154-3372-00 Cardinal 10 capsules — AA FDA listed —
Benzonatate 100 mg 60429-0927-01 Golden 100 capsules — AA FDA listed —
Benzonatate 100 mg 60760-0700-30 St. 30 capsules — AA FDA listed —
Benzonatate 100 mg 60760-0869-15 St. 15 capsules — AA FDA listed —
Benzonatate 100 mg 61919-0400-20 DIRECT 20 capsules — AA FDA listed —
Benzonatate 100 mg 63187-0076-14 Proficient 14 capsules — AA FDA listed —
Benzonatate 100 mg 63187-0799-14 Proficient 14 capsules — AA FDA listed —
benzonatate 100 mg 63187-0928-10 Proficient 10 capsules — AA FDA listed —
Benzonatate 100 mg 63629-2473-01 Bryant 500 capsules — AA FDA listed —
Benzonatate 100 mg 63629-2474-01 Bryant 100 capsules — AA FDA listed —
Benzonatate 100 mg 63629-9189-01 Bryant 500 capsules — AA FDA listed —
Benzonatate 100 mg 65162-0536-10 Amneal 100 capsules — AA FDA listed —
Benzonatate 100 mg 65841-0614-01 Zydus 100 capsules — AA FDA listed —
Benzonatate 100 mg 67046-1484-03 Coupler 30 capsules — AA FDA listed —
Benzonatate 100 mg 67046-1629-03 Coupler 30 capsules — AA FDA listed —
Benzonatate 100 mg 67296-2194-01 Redpharm 15 capsules — AA FDA listed —
Benzonatate 100 mg 67296-2207-01 Redpharm 15 capsules — AA FDA listed —
Benzonatate 100 mg 68071-5083-03 NuCare 30 capsules — AA FDA listed —
Benzonatate 100 mg 68071-5105-04 NuCare 4 capsules — AA FDA listed —
Benzonatate 100 mg 68071-5156-02 NuCare 20 capsules — AA FDA listed —
Benzonatate 100 mg 68071-5223-04 NuCare 4 capsules — AA FDA listed —
Benzonatate 100 mg 68094-0798-50 Precision 100 capsules — AA FDA listed —
Benzonatate 100 mg 68788-7607-00 Preferred 9 capsules — AA FDA listed —
Benzonatate 100 mg 70518-2873-00 REMEDYREPACK 10 capsules — AA FDA listed —
Benzonatate 100 mg 70518-4558-00 REMEDYREPACK 30 capsules — AA FDA listed —
Benzonatate 100 mg 71205-0067-10 Proficient 10 capsules — AA FDA listed —
Benzonatate 100 mg 71205-0632-10 Proficient 10 capsules — AA FDA listed —
Benzonatate 100 mg 71205-0699-10 Proficient 10 capsules — AA FDA listed —
Benzonatate 100 mg 71205-0853-00 Proficient 100 capsules — AA FDA listed —
benzonatate 100 mg 71205-0971-00 Proficient 100 capsules — AA FDA listed —
Benzonatate 100 mg 71335-0091-00 Bryant 10 capsules — AA FDA listed —
benzonatate 100 mg 71335-0688-00 Bryant 10 capsules — AA FDA listed —
benzonatate 100 mg 71335-1329-00 Bryant 10 capsules — AA FDA listed —
Benzonatate 100 mg 71335-1544-00 Bryant 10 capsules — AA FDA listed —
Benzonatate 100 mg 71335-1927-00 Bryant 10 capsules — AA FDA listed —
Benzonatate 100 mg 71335-1968-00 Bryant 10 capsules — AA FDA listed —
Benzonatate 100 mg 71335-2672-01 Bryant 500 capsules — AA FDA listed —
Benzonatate 100 mg 71335-3068-00 Bryant 10 capsules — AA FDA listed —
Benzonatate 100 mg 71610-0692-30 Aphena 30 capsules — AA FDA listed —
Benzonatate 100 mg 72162-1561-01 Bryant 100 capsules — AA FDA listed —
Benzonatate 100 mg 72189-0194-20 DIRECT 20 capsules — AA FDA listed —
Benzonatate 100 mg 72789-0230-06 PD-Rx 6 capsules — AA FDA listed —
Benzonatate 100 mg 72789-0231-15 PD-Rx 15 capsules — AA FDA listed —
Benzonatate 100 mg 72865-0117-01 XLCare 100 capsules — AA FDA listed —
Benzonatate 100 mg 76420-0803-01 Asclemed 100 capsules — AA FDA listed —
Benzonatate 100 mg 85766-0066-01 Sportpharm 100 capsules — AA FDA listed —
Benzonatate 100 mg 85766-0089-01 Sportpharm 100 capsules — AA FDA listed —
Benzonatate 100 mg 00615-8661-05 NCS 15 capsules — AA FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2024
On the market since
Sep 2024
📍
2026
Currently FDA-listed
2 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 23155-0898-01, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
458
Units reimbursed last 4 qtrs
14K
Gross reimbursed last 4 qtrs
$4.9K
Avg / prescription
$10.64
Avg / unit
$0.3480
Latest quarter Q1 2026
349Rx
Medicaid pays / ea
$0.3480
gross reimbursed
vs
NADAC / ea
$0.0656
acquisition cost
=
Spread
+$0.2824
+430% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
67% FFS 33% MCO
Fee-for-service · 307 Rx Managed care · 151 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 307 units · 3.1 per 100k residents MI New York: 5,056 units · 25.8 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: no data reported OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 1,892 units · 16.1 per 100k residents OH Pennsylvania: 823 units · 6.3 per 100k residents PA New Jersey: 794 units · 8.5 per 100k residents NJ Massachusetts: no data reported MA California: 3,149 units · 8.1 per 100k residents CA Utah: no data reported UT Colorado: 315 units · 5.4 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: no data reported KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: 1,357 units · 22.0 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: no data reported NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: no data reported FL
Units reimbursed · per 100k residents
3.125.8
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 New York 25.8 /100k
2 Maryland 22.0 /100k
3 Ohio 16.1 /100k
4 New Jersey 8.5 /100k
5 California 8.1 /100k
6 Pennsylvania 6.3 /100k
7 Colorado 5.4 /100k
8 Michigan 3.1 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

💊 Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
500 capsules23155-0898-05 2,327 Rx · $22,917
100 capsules this page23155-0898-01 458 Rx · $4,874
Drug total (last 4 qtrs): 2,785 Rx · 92,419 units · $27,791 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Benzonatate — the program that covers self-administered drugs. 12 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Benzonatate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$654.6K
Claims incl. refills
49.4K
Beneficiaries
42.4K
Spend / beneficiary
$15.42
Spend / claim
$13.25
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

📦 Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startStatus
23155-0898-01 You're viewing this 100 CAPSULE, LIQUID FILLED in 1 BOTTLE (23155-898-01) $0.0656 / ea $6.56 2024-09-29 Active
23155-0898-05 500 CAPSULE, LIQUID FILLED in 1 BOTTLE (23155-898-05) $0.0656 / ea $32.80 2024-09-29 Active

You're viewing the smallest of 2 pack sizes for this product.

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.0656 NADAC).

This pack accounts for about 16% of this product's recent Medicaid fills; most go to the 500 capsules pack. See all packs ↓

Pack size FAQ

What quantity is in NDC 23155-0898-01?
NDC 23155-0898-01 is a 100-count package — 100 capsule, liquid filled in 1 bottle.
What is the difference between NDC 23155-0898-01 and NDC 23155-0898-05?
Both are Benzonatate 100 mg Capsule, Liquid Filled — the drug itself is identical. NDC 23155-0898-01 is the 100-count package, while NDC 23155-0898-05 is the 500 capsules package.
What NDC number is used to bill for this package of Benzonatate 100 mg Capsule, Liquid Filled?
Bill NDC 23155-0898-01 — the 11-digit billing format is 23155089801. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description
🎯 Indications and Usage 12 words ▾

INDICATIONS AND USAGE Benzonatate is indicated for the symptomatic relief of cough.

⏱️ Dosage and Administration 64 words ▾

DOSAGE AND ADMINISTRATION Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given . Benzonatate should be swallowed whole. Benzonatate Capsules are not to be broken, chewed, dissolved, cut or crushed.

⛔ Contraindications 7 words ▾

CONTRAINDICATIONS Hypersensitivity to benzonatate or related compounds.

⚠️ Warnings 131 words ▾

WARNINGS Hypersensitivity Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures. Psychiatric Effects Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking benzonatate in combination with other prescribed drugs.

Accidental Ingestion and Death in Children Keep benzonatate out of reach of children. Accidental ingestion of benzonatate resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15 to 20 minutes and death has been reported within one hour of ingestion.

If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE ).

🤒 Adverse Reactions 90 words ▾

ADVERSE REACTIONS Potential Adverse Reactions to benzonatate may include: Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule. CNS: sedation; headache; dizziness; mental confusion; visual hallucinations. GI: constipation; nausea; GI upset.

Dermatologic: pruritus; skin eruptions. Other: nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity. Deliberate or accidental overdose has resulted in death, particularly in children.

To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🆘 Overdosage 209 words ▾

OVERDOSAGE Intentional and unintentional overdose may result in death, particularly in children. The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.

Signs and Symptoms: The signs and symptoms of overdose of benzonatate have been reported within 15 to 20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise. CNS stimulation may cause restlessness and tremors, which may proceed to clonic convulsions followed by profound CNS depression.

Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion. Treatment: In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry.

Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage.

Do not use CNS stimulants.

🧬 Clinical Pharmacology 61 words ▾

CLINICAL PHARMACOLOGY Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.

📦 How Supplied / Storage and Handling 104 words ▾

HOW SUPPLIED Benzonatate Capsules, USP are available as: 100 mg Oval Shape, imprint “100” with white ink, transparent yellow soft gelatin capsule NDC 23155-898-01 Bottles of 100 NDC 23155-898-05 Bottles of 500 200 mg Oblong Shape, imprint “200” with white ink, transparent yellow soft gelatin capsules NDC 23155-899-01 Bottles of 100 NDC 23155-899-05 Bottles of 500 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in tight, light-resistant container as defined in the USP.

Distributed by: Avet Pharmaceuticals Inc. East Brunswick, NJ 08816 1.866.901.DRUG (3784) 51U000000461US01 Revised: 04/2024 image description

📋 Description 84 words ▾

DESCRIPTION Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7. Benzonatate Capsules, USP contain 100 mg or 200 mg of benzonatate, USP. Benzonatate Capsules also contain: D&C Yellow No.

10, gelatin, glycerin, methylparaben sodium and propylparaben sodium. The white imprinting ink contains the following inactive ingredients: ammonium hydroxide, isopropyl alcohol, n-butyl alcohol, propylene glycol, shellac glaze, simethicone and titanium dioxide. FDA approved dissolution test specifications differ from USP. structure

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 23155-0894-06 · Heritage 23155-0899-01 · Heritage →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.